Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Study backs Nymox's urine test for Alzheimer's:

This article was originally published in Clinica

Executive Summary

Nymox says that a double-blind, 139-participant, US study of its AlzheimAlert urine test for Alzheimer's disease has provided further evidence to validate the product. The test, which is already available in the US, identifies a brain protein (neural thread protein) known to be elevated in Alzheimer's patients. The new study, to be published in an upcoming issue of Alzheimer's Reports, also underlined the test's potential for monitoring disease progression and response to treatment, after higher levels of the protein were found in later stage Alzheimer's cases than earlier stage cases, says the Maywood, New Jersey firm.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts